Guizhou Bailing Group Pharmaceutical Co., Ltd. (SHE:002424)
China · Delayed Price · Currency is CNY 4.580
+0.040 (0.88%)
Jul 29, 2026, 3:04 PM CST
SHE:002424 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 6,252 | 5,938 | 5,255 | 11,236 | 11,404 | 10,622 | |
Market Cap Growth | -14.55% | 12.99% | -53.23% | -1.47% | 7.37% | -3.87% |
Enterprise Value | 7,221 | 6,965 | 6,933 | 12,721 | 12,731 | 12,179 |
Last Close Price | 4.58 | 4.35 | 3.85 | 8.11 | 8.16 | 7.60 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | 156.31 | - | 82.36 | 89.65 |
Forward PE | - | 11.00 | 11.00 | 29.49 | 17.71 | 17.71 |
PS Ratio | 2.13 | 1.95 | 1.37 | 2.64 | 3.22 | 3.41 |
PB Ratio | 1.95 | 1.87 | 1.64 | 3.42 | 2.85 | 2.74 |
P/TBV Ratio | 2.11 | 2.02 | 1.78 | 3.69 | 3.03 | 2.92 |
P/FCF Ratio | 13.31 | 9.52 | - | 519.03 | 26.30 | - |
P/OCF Ratio | 10.49 | 7.93 | 582.59 | 89.34 | 22.71 | 32.69 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.46 | 2.29 | 1.81 | 2.98 | 3.60 | 3.92 |
EV/EBITDA Ratio | 31.31 | 31.39 | 55.27 | - | 38.96 | 38.29 |
EV/EBIT Ratio | 67.74 | 64.49 | 353.32 | - | 56.98 | 54.65 |
EV/FCF Ratio | 15.37 | 11.17 | - | 587.59 | 29.35 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.35 | 0.39 | 0.56 | 0.51 | 0.39 | 0.44 |
Debt / EBITDA Ratio | 4.91 | 5.35 | 13.16 | - | 4.62 | 5.20 |
Debt / FCF Ratio | 2.41 | 1.97 | - | 77.89 | 3.61 | - |
Net Debt / Equity Ratio | 0.30 | 0.28 | 0.44 | 0.39 | 0.24 | 0.32 |
Net Debt / EBITDA Ratio | 4.28 | 3.94 | 11.16 | -4.26 | 2.95 | 3.93 |
Net Debt / FCF Ratio | 2.03 | 1.40 | -42.44 | 58.59 | 2.22 | -12.39 |
Asset Turnover | 0.45 | 0.46 | 0.53 | 0.60 | 0.53 | 0.46 |
Inventory Turnover | 1.89 | 1.87 | 1.46 | 1.98 | 1.76 | 1.58 |
Quick Ratio | 0.67 | 0.71 | 0.64 | 0.73 | 1.07 | 1.09 |
Current Ratio | 0.95 | 0.97 | 0.96 | 1.06 | 1.38 | 1.45 |
Return on Equity (ROE) | -3.12% | -3.24% | 1.14% | -11.33% | 3.46% | 2.81% |
Return on Assets (ROA) | 1.02% | 1.01% | 0.17% | -3.52% | 2.09% | 2.06% |
Return on Invested Capital (ROIC) | -6.46% | -6.36% | 0.24% | -8.46% | 3.79% | 3.35% |
Return on Capital Employed (ROCE) | 3.20% | 3.20% | 0.60% | -11.20% | 5.40% | 5.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -1.61% | -1.76% | 0.64% | -3.69% | 1.21% | 1.11% |
FCF Yield | 7.51% | 10.50% | -0.63% | 0.19% | 3.80% | -0.95% |
Payout Ratio | - | - | 241.94% | - | 62.50% | 84.56% |
Buyback Yield / Dilution | 18.39% | 22.40% | -21.67% | 0.22% | 6.50% | -6.92% |
Total Shareholder Return | 18.39% | 22.40% | -21.67% | 0.22% | 6.50% | -6.92% |